Quantcast

Latest Vascular endothelial growth factor Stories

2014-03-24 12:30:49

LONDON, March 24, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Analysis of the US Retinal Therapeutics Market Improvements in Administration and Efficacy Drive GrowthSince the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research...

2014-03-21 08:24:23

ROCKVILLE, Md., March 21, 2014 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three and 12 months ended December 31, 2013. http://photos.prnewswire.com/prnvar/20010620/ENMDLOGO The Company reported a net loss of ($1.3 million), or ($0.05) per share for the three months ended December 31, 2013. This compares with net loss of ($0.4...

2014-03-12 12:29:13

Surveyed U.S. Payers Look for Substantial Delivery Achievements for Inclusion of New Agents in Formularies, According to Findings from Decision Resources Group BURLINGTON, Mass., March 12, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European retinal specialists ascribe a moderate to high unmet need for wet age-related macular degeneration (AMD) therapies that improve visual acuity. In line with this finding, surveyed U.S. retinal specialists expect that they...

2014-03-10 04:21:04

LEUVEN, Belgium, March 10, 2014 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a EUR3 million grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant funding will be used by ThromboGenics to support research into potential new biotherapeutics for the...

2014-03-04 12:25:51

SAN DIEGO and OSAKA, Japan, March 4, 2014 /PRNewswire/ -- TRACON Pharmaceuticals (TRACON) and Santen Pharmaceutical Co., Ltd. (Santen) announced today that they have entered into an exclusive agreement for the development and global commercialization of TRACON's anti-endoglin antibodies, including TRC105, in ophthalmology. Pre-clinical and clinical data from TRACON's ongoing development of TRC105 in combination with anti-VEGF products in oncology indicate inhibiting both the...

2014-03-03 04:22:41

TARRYTOWN, N.Y., March 3, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA(®) (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare (MHLW). "Clinically significant DME is a leading cause of vision loss in the working-age...

2014-02-24 08:27:50

TARRYTOWN, N.Y., Feb. 24, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA(®) (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA is ten months from...

2014-02-11 08:33:10

CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in an open label single-arm Phase 2 clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) in patients with relapsed ovarian cancer. The Phase 2 combination therapy trial of this investigational treatment is being conducted at Massachusetts General Hospital (MGH) and...

2014-02-10 08:26:04

TARRYTOWN, N.Y., Feb. 10, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VISTA-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100, compared to...

2014-02-06 08:29:32

American Academy of Ophthalmology advises that early detection and today's treatments for common eye disease among seniors can help stop vision loss SAN FRANCISCO, Feb. 6, 2014 /PRNewswire/ -- While age-related macular degeneration (AMD) is the leading cause of new cases of blindness in Americans age 65 and older[1], seniors who develop AMD should not consider blindness in advanced age to be inevitable, according to the American Academy of Ophthalmology. During AMD Awareness Month, the...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.